Evidence map›Paper›PMID 35971127›Full record

ArticleCell communication and signaling : CCS2022

Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.

Ping Zhu, Zhengxin Jin, Guiyu Kang, Yanfei Jia, Duanrui Liu, Qian Zhang, Feiyang Guo, Ying Jia, Yang Jiao, Jingtan Li and 2 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Cell communication and signaling : CCS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. FeInternational journal of nanomedicine · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ping ZhuResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Zhengxin JinResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Guiyu KangDepartment of Medical Laboratory, Weifang Medical University, Weifang, China.
Yanfei JiaResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Duanrui LiuResearch Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, China.
Qian ZhangResearch Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, China.
Feiyang GuoCollege of Life Science, Shandong Normal University, Jinan, China.
Ying JiaResearch Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, China.
Yang JiaoResearch Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, China.
Jingtan LiResearch Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, China.
Haiji SunCollege of Life Science, Shandong Normal University, Jinan, China.
Xiaoli MaResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China. Maxiaoli_jn@sdu.edu.cn.
Jinan Central Hospital · CNShandong University · CNShandong Normal University · CNShandong First Medical University · CNWeifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy has proven to be an emerging treatment for non-small-cell lung cancer in recent years. Notably, smokers show higher programmed cell death ligand-1 (PD-L1) expression and better responses to PD-1/PD-L1 inhibitors than nonsmokers. Genome-wide association studies show that the CHRNΑ5 encoding α5-nicotinic acetylcholine receptor (α5-nAChR) is especially relevant to lung cancer and nicotine dependence. Jab1 is a key regulatory factor and promotes the stabilization of PD-L1. Our previous study reported that α5-nAChR mediates lung adenocarcinoma (LUAD) epithelial-mesenchymal transition (EMT) and metastasis via STAT3/Jab1. However, the link between α5-nAChR and PD-L1 is unclear in LUAD.

methodsWe used various bioinformatics databases to analyze the expression of related genes and their correlations. Expression and clinicopathologic significance of α5-nAChR and PD-L1 were detected by immunohistochemistry in a tissue microarray. α5-nAChR regulated LUAD cell immune escape by targeting the STAT3/Jab1-PD-L1 signalling by Western-blotting and ChIP in vitro. We used T cell coculture, flow cytometry, ELISA, CCK8 assay and crystal violet staining to detect the expression of regulatory T cell (Tregs), IFN-γ, IL-2 and the ability of T cell-mediated tumour cell killing respectively. IF assays were performed in both cancer cells and tumour xenograft paraffin sections to analyze the protein expression. The in vivo experiments in mouse model were performed to show the α5-nAChR-mediated immune escape via PD-L1 pathway.

resultsThe expression of α5-nAChR was correlated with PD-L1 expression, smoking status and lower survival of LUAD in vivo. In vitro, the expression of α5-nAChR mediated phosphorylated STAT3 (pSTAT3), Jab1 and PD-L1 expression. STAT3 bound to the Jab1 or PD-L1 promoter and mediated PD-L1 expression. Jab1 stabilized PD-L1 expression in LUAD cells. Furthermore, in primary T cell cocultured system, downregulation of α5-nAChR suppressed the function of CD4

conclusionsOur results suggest that the novel α5-nAChR/STAT3-Jab1-PD-L1 axis is involved in LUAD immune escape, which could lead to potential therapeutic strategies for cancer immunotherapy. Video abstract.

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsReceptors, NicotinicAnimalsB7-H1 AntigenCell Line, TumorGenome-Wide Association StudyHumansInterleukin-2MiceSTAT3 Transcription FactorB7-H1 AntigenInterleukin-2Receptors, NicotinicSTAT3 protein, humanSTAT3 Transcription FactorImmune escapeLung adenocarcinomaSTAT3/Jab1-PD-L1α5-nAChR

Identifiers

PMID35971127
PMCPMC9377093
OpenAlexW4291512004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.